Vectibix (panitumumab) — HCPCS J9303

About Vectibix (panitumumab)

Vectibix is the brand name for panitumumab, a fully human IgG2 monoclonal antibody that targets the epidermal growth factor receptor (EGFR / HER1) on the surface of tumor cells. By binding EGFR and blocking ligand binding, panitumumab inhibits downstream RAS/RAF/MAPK and PI3K/AKT signaling that drives colorectal cancer proliferation. Vectibix was first approved by the FDA on September 27, 2006 as monotherapy for EGFR-expressing mCRC after failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy. The label was expanded in 2014 to include first-line use in combination with FOLFOX for patients with RAS wild-type mCRC, after the PRIME study (Douillard et al., NEJM 2013) demonstrated that anti-EGFR therapy is ineffective — and may worsen outcomes — in tumors with activating RAS mutations.

Vectibix is manufactured by Amgen and is supplied as a clear, colorless, sterile solution at 20 mg/mL in three single-dose vial sizes: 100 mg/5 mL, 200 mg/10 mL, and 400 mg/20 mL. It is administered as an intravenous infusion every two weeks. The current FDA-approved indication scope is strictly RAS wild-type mCRC; biller workflow must confirm the molecular pathology report (extended-RAS panel) is on file before authorizing the first dose, and the payer's prior authorization will reference the pathology result directly. The companion-diagnostic gate is the single most important pre-billing checkpoint for J9303.

Operationally, Vectibix is a buy-and-bill medical-benefit drug administered in oncology offices, ambulatory infusion centers, and hospital outpatient departments. The first infusion runs 90 minutes; subsequent infusions run 60 minutes if the first was tolerated. No infusion-reaction premedication is required — a material chair-time and operational advantage over Erbitux (cetuximab), the chimeric anti-EGFR antibody used for the same indication.

Vectibix vs Erbitux — anti-EGFR disambiguation FDA labels verified May 2026

Same target (EGFR), same RAS WT indication, but two different drugs with different J-codes and different billing/operational profiles. Confirm which agent was administered before posting the claim.

Dosing & infusion timing FDA label + NCCN CRC v2.2026

Single approved regimen: 6 mg/kg IV q2wk for adults with RAS wild-type mCRC. Use as monotherapy after chemo failure or in combination with FOLFOX in the first line.

Unit-math worked examples (J9303 = 10 mg per unit)

• 60 kg patient × 6 mg/kg = 360 mg → 36 units administered. Draw one 400 mg vial; 40 mg waste = 4 JW units.
• 75 kg patient × 6 mg/kg = 450 mg → 45 units administered. Draw one 400 mg + one 100 mg vial = 500 mg drawn; 50 mg waste = 5 JW units.
• 80 kg patient × 6 mg/kg = 480 mg → 48 units administered. Draw one 400 mg + one 100 mg vial = 500 mg drawn; 20 mg waste = 2 JW units.
• 100 kg patient × 6 mg/kg = 600 mg → 60 units administered. Draw one 400 mg + one 200 mg vial = 600 mg; JZ, no waste.

Infusion timing

Administer the first infusion of Vectibix over 90 minutes via low-protein-binding 0.2 or 0.22 micron in-line filter. If the first infusion is tolerated, subsequent infusions may be given over 60 minutes. Doses higher than 1,000 mg should be administered over 90 minutes regardless of dose number. Reduce infusion rate by 50% for grade 1 or 2 infusion reactions; immediately and permanently discontinue for grade 3 or 4 reactions. Do not administer as an IV push or bolus.

Dose modification for skin toxicity

Withhold for grade 3 or 4 dermatologic reaction or for life-threatening complications of inflammatory or infectious sequelae. If toxicity improves to grade 2 or less within 1 month, resume at 50% of the original dose, then increase by 25% per cycle if tolerated up to the original 6 mg/kg dose. If reactions do not improve within 1 month or recur after dose reduction, permanently discontinue.

NDC reference — Vectibix (Amgen labeler 55513) FDA NDC Directory verified May 2026

Three single-dose vials, all 20 mg/mL. Pad NDCs to 11 digits for CMS-1500 Box 24A.

Storage & handling

Store vials refrigerated at 2°C to 8°C (36°F to 46°F) in the original carton; protect from light. Do not freeze; do not shake. Diluted infusion solution is stable for up to 24 hours under refrigeration and up to 6 hours at room temperature. Doses up to and including 1,000 mg are diluted to a final volume of 100 mL with 0.9% sodium chloride; doses greater than 1,000 mg are diluted to a final volume of 150 mL. Do not exceed a final concentration of 10 mg/mL.

Administration codes CPT verified May 2026

Vectibix is HCPCS chemo-classified. Use 96413 for the first hour and 96415 for the second hour when the initial 90-minute infusion crosses the second hour. Subsequent 60-minute infusions: 96413 alone.

Infusion-time billing per dose

• First infusion (90 min): 96413 × 1 + 96415 × 1 (additional hour is billed when infusion exceeds the initial hour by > 30 minutes per CPT timing rules).
• Subsequent infusions (60 min): 96413 × 1 (no add-on; falls within the initial hour).
• Doses > 1,000 mg (any infusion number): 90-minute infusion required → 96413 + 96415.
• FOLFOX sequential agents: oxaliplatin and infusional 5-FU billed under their own admin codes (96413 for the initial chemo, 96417 for each additional sequential chemo) on the same encounter.

Modifiers — JZ, JW, and the weight-based waste calculation CMS verified May 2026

Effective 7/1/2023, every single-dose-container claim requires JZ (no waste) or JW (waste reported on a separate line). Vectibix is dosed by mg/kg, so partial-vial waste is common and JW is the typical modifier.

JZ — required when no drug is discarded

Append JZ to the J9303 line when the dose lands cleanly on a vial combination (e.g., a 100 kg patient at 6 mg/kg = 600 mg, drawn from one 400 mg + one 200 mg vial with no waste). JZ is uncommon for Vectibix because mg/kg dosing rarely matches an integer combination of 100 / 200 / 400 mg vials — but it applies when it does.

JW — required for documented waste of unused single-dose-vial drug

For most weight-based Vectibix doses, partial-vial waste is the norm. Bill the administered units with JZ on the primary line and the discarded units with JW on a separate line, same date of service. Document the discarded amount in the medical record per CMS guidance.

Apply each MAC's rounding convention. Some MACs require billing the total drawn from the vial as administered units and reporting waste only when an entire additional vial would otherwise have been required. Refer to your local MAC billing article for the exact rounding rule.

JG / TB — 340B drug pricing

Hospitals that purchase Vectibix through 340B and bill Medicare report JG (acute-care hospitals) or TB (rural sole community / critical-access hospitals), per CMS guidance. Most physician-office and ambulatory infusion sites do not use 340B pricing; only the hospital-outpatient setting does.

Modifier 25 — same-day E/M

Append modifier 25 to the same-day E/M code when a significant, separately identifiable evaluation occurred (clinical reassessment for next-cycle decision, dose-modification review for skin toxicity, treatment-decision encounter, etc.). Routine pre-infusion check-in is bundled.

ICD-10-CM diagnosis codes FY2026 verified May 2026

Vectibix has a single FDA-approved indication: RAS wild-type metastatic colorectal cancer. ICD-10 selection follows primary site (colon or rectum) and stage (mets required).

Site of care & place of service Verified May 2026

Vectibix is given in oncology offices, freestanding ambulatory infusion centers, and hospital outpatient departments. The 60-minute infusion (post-first-dose) fits cleanly into any infusion setting.

Payer site-of-care steering

UnitedHealthcare, Aetna, Cigna, and most BCBS plans apply site-of-care UM to specialty infusion drugs. For Vectibix, payers typically prefer office (POS 11) or in-network AIC (POS 49) where facility fees are lower. Hospital-outpatient (POS 19/22) requires medical-necessity justification under most commercial UM policies. The 60-minute subsequent infusion duration and lack of premed make Vectibix straightforward to deliver in non-hospital settings.

Claim form field mapping Amgen billing guide

CMS-1500 / 837P (physician office, AIC; POS 11/49) example for a 480 mg dose (80 kg patient at 6 mg/kg).

Source: Amgen Vectibix Billing & Coding Reference (2024); CMS HCPCS quarterly update.

Payer policy snapshot Reviewed May 2026

Prior authorization is universal. Coverage hinges on documented RAS WT status (extended-RAS panel) plus appropriate line-of-therapy criteria.

What to document for PA approval

• Molecular pathology report showing KRAS WT (exons 2, 3, 4) AND NRAS WT (exons 2, 3, 4)
• Documentation of metastatic colorectal cancer with site of mets (liver, lung, peritoneal, nodal)
• For monotherapy line: documented failure of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing regimens (drug names, dates, response/progression evidence)
• For first-line use: confirmation that Vectibix will be combined with FOLFOX
• ECOG performance status (typically 0–2)
• Baseline serum magnesium (for hypomagnesemia monitoring)

Medicare reimbursement CMS Q2 2026 (live)

Quarterly ASP from CMS Part B Drug Pricing File. Effective April 1 – June 30, 2026 based on Q4 2025 ASP submissions.

Per-dose worked example (J9303 = 10 mg per unit)

• 60 kg patient (360 mg): 36 units × ASP+6% = $6,277.90
• 75 kg patient (450 mg): 45 units × ASP+6% = $7,847.37
• 80 kg patient (480 mg): 48 units × ASP+6% = $8,370.53
• 100 kg patient (600 mg): 60 units × ASP+6% = $10,463.16

ASP refreshes quarterly. Sequestration applies an approximately 2% reduction to allowed amounts; actual paid is roughly ASP + 4.3%. Wasted drug billed on the JW line is also reimbursable per the CMS single-dose container policy effective 7/1/2023.

Coverage

No NCD specific to panitumumab. Each MAC publishes a billing and coding article covering Vectibix with the covered ICD-10 ranges for mCRC and the documentation requirements for RAS WT status. All MACs cover J9303 for the FDA-approved on-label mCRC indication when the medical record supports the RAS WT requirement.

Canonical pricing source: CMS Medicare Part B Drug ASP Pricing File.

Patient assistance — Amgen Assist 360 Amgen 2026 verified May 2026

• Amgen Assist 360: phone 1-888-4ASSIST (1-888-427-7478), Mon–Fri 8 AM – 8 PM ET. The integrated patient-support hub covers benefits investigation, prior authorization assistance, appeals support, and copay program enrollment for Vectibix and other Amgen oncology products. Web: amgenassist360.com.
• Vectibix Co-Pay Program (commercially insured): reduces out-of-pocket cost; eligibility excludes federal-program beneficiaries (Medicare, Medicaid, VA, TRICARE). Enroll through Amgen Assist 360.
• Amgen Safety Net Foundation: free Vectibix for qualifying uninsured or underinsured patients meeting financial criteria (typically ≤ 500% FPL; varies). Apply via Amgen Assist 360.
• Independent foundations (Medicare patients): PAN Foundation (Colorectal Cancer fund), HealthWell Foundation (Colorectal Cancer fund), CancerCare Co-Payment Assistance Foundation. Fund status and FPL thresholds vary — check open-fund status quarterly.
• Bridge supply: Amgen Assist 360 can coordinate a temporary free supply during benefit-verification or PA-appeal delays, subject to eligibility.

Common denials & how to fix them

Frequently asked questions

What is the HCPCS code for Vectibix?

Vectibix (panitumumab) is billed under J9303 — "Injection, panitumumab, 10 mg." One billable unit equals 10 mg, not 1 mg. A typical 6 mg/kg dose for an 80 kg patient is 480 mg = 48 units. Vectibix is distinct from Erbitux (cetuximab, J9055) — same EGFR target but different drug, different code, different infusion duration, and different premedication requirements.

How is Vectibix different from Erbitux (cetuximab)?

Both are anti-EGFR monoclonal antibodies for RAS wild-type mCRC, but they are not interchangeable for billing. Vectibix (panitumumab, J9303) is a fully human IgG2 mAb dosed at 6 mg/kg IV q2wk over 60 minutes (90 minutes for the first infusion) with no routine premedication. Erbitux (cetuximab, J9055) is a chimeric (mouse-human) IgG1 mAb dosed weekly (400 mg/m² loading then 250 mg/m² weekly) or biweekly (500 mg/m² q2wk) over 60–120 minutes with required diphenhydramine premedication for infusion reactions. Confirm the drug administered matches the J-code billed.

RAS testing — which gene panel is required?

The current FDA label requires extended-RAS testing: KRAS and NRAS, exons 2 (codons 12, 13), 3 (codons 59, 61), and 4 (codons 117, 146). All loci must be wild-type. Pre-2014 KRAS-exon-2-only testing is no longer sufficient — payers will deny on the narrower panel. If the pathology report cites only KRAS exon 2, request a reflex extended-RAS analysis from the lab using archived tissue.

Why no premed for Vectibix but yes for Erbitux?

Vectibix is a fully human IgG2 antibody and elicits a substantially lower rate of infusion reactions than Erbitux, which is a chimeric (mouse-human) IgG1 antibody with non-human Fab regions and a galactose-α-1,3-galactose carbohydrate epitope that triggers IgE-mediated hypersensitivity in some patients. The FDA labels reflect this difference: Erbitux requires diphenhydramine premedication; Vectibix does not require routine premedication for infusion reactions. (Skin-toxicity prophylaxis with doxycycline and topicals is recommended for both.)

1L vs 2L+ mCRC billing differences?

For first-line use, Vectibix is combined with FOLFOX (infusional 5-FU/leucovorin + oxaliplatin) — the claim must include admin codes for the FOLFOX agents (96413 initial + 96417 for sequential agents) plus the oxaliplatin and 5-FU drug J-codes. For monotherapy use (after fluoropyrimidine-, oxaliplatin-, and irinotecan-containing failure), the prior chemotherapy history must be documented in the PA submission with regimen names, dates, and response/progression evidence. Either way, J9303 + 96413 (± 96415 for first 90-min dose) is the same drug + admin pairing.

Skin toxicity prophylaxis — what to document?

The STEPP trial established that prophylactic dermatologic care reduces grade 2+ skin toxicity by roughly half vs reactive treatment. Document on day 1 of cycle 1 and continue for the first 6 weeks: oral doxycycline 100 mg BID (or minocycline 100 mg BID), topical hydrocortisone 1% cream, broad-spectrum sunscreen SPF 15+, and a daily skin moisturizer. Grade each cycle on the CTCAE scale; show any dose-modification decisions for grade 3+ events. Payers increasingly request this documentation for continued authorization.

Hypomagnesemia management?

Hypomagnesemia is a class effect of anti-EGFR therapy. Monitor serum magnesium and calcium prior to each Vectibix dose and for 8 weeks after the final dose. Replete with IV magnesium sulfate as needed; severe or persistent grade 3–4 hypomagnesemia may require dose interruption. Maintain a monitoring log in the chart — payer audits cite missing magnesium labs as a denial reason for renewal authorization.

Pediatric eligibility?

Vectibix is not approved for pediatric patients. Safety and effectiveness have not been established. Pediatric mCRC is extraordinarily rare; off-label pediatric anti-EGFR use is not a recognized indication and is not covered by major payers.

What is the Q2 2026 Medicare reimbursement for J9303?

Q2 2026 ASP + 6% for J9303 is approximately $174.386 per 10 mg unit. A typical 6 mg/kg dose for an 80 kg patient = 480 mg = 48 units × $174.386 = $8,370.53 before sequestration. Sequestration applies an approximately 2% reduction; actual paid is roughly ASP + 4.3%. ASP refreshes quarterly — see the live snapshot above for current values.

Source documents

1. AAPC — HCPCS J9303 (Vectibix)
   Code descriptor and crosswalk reference
2. DailyMed — Vectibix (BLA 125147)
   Current FDA prescribing information — June 2025 revision; dosing; boxed dermatologic toxicity warning; RAS WT mCRC and KRAS G12C + sotorasib indications
3. Amgen Assist 360 — patient support hub
   Benefits investigation, PA support, copay program, and Safety Net Foundation enrollment for Vectibix
4. Amgen — Vectibix product page
   Manufacturer product information and billing resources
5. Douillard JY et al. — PRIME study (NEJM 2013)
   Panitumumab + FOLFOX4 vs FOLFOX4 alone in first-line mCRC; established extended-RAS WT requirement
6. Price TJ et al. — ASPECCT study (JCO 2014)
   Panitumumab vs cetuximab head-to-head in chemo-refractory KRAS WT mCRC; non-inferiority of panitumumab
7. NCCN Clinical Practice Guidelines — Colon Cancer (v2.2026)
   Vectibix line-of-therapy recommendations for RAS WT mCRC
8. NCCN Clinical Practice Guidelines — Rectal Cancer (v2.2026)
   Vectibix use in RAS WT metastatic rectal cancer
9. CMS — Medicare Part B Drug ASP Pricing File
   Q2 2026 quarterly file (J9303 panitumumab pricing)
10. CMS — HCPCS quarterly update file
    Canonical HCPCS code source for J9303
11. CMS — JW / JZ modifier guidance
    Single-dose-container waste reporting (effective 7/1/2023)
12. UnitedHealthcare — Medical drug policy database
    PA criteria for J9303 with extended-RAS testing requirements
13. Aetna — Clinical policy bulletins (oncology drugs)
    Vectibix PA criteria and indication scope